James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Selection of first-line treatments and the rational sequencing of therapies are the focus of current research in the treatment of pancreatic neuroendocrine tumors (NETs).
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Using more accurately defined data than previous studies, a team of investigators at the UCSD School of Medicine has characterized the epidemiology of GIST.
The number of therapies available for the treatment of metastatic colorectal cancer (mCRC) has increased dramatically since the mid-1990s, when the only option approved by the FDA was 5-fluorouracil (5-FU).
Hepatocellular carcinoma remains one of the most common tumors worldwide, and frequently carries a poor prognosis, with most patients being diagnosed at late stages of disease.
As with most cancers, early diagnosis and treatment of hepatocellular carcinoma (HCC) may result in more effective treatment and improved outcomes. Unfortunately, most patients with HCC are diagnosed at a late stage, when therapeutic options are limited and prognosis is poor.
JTT Articles
CD19-Targeted Agents Continue to Show Positive Outcomes
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
Graft Versus Host Disease for the General Oncologist
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.